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Introduction
The EGF receptor (EGFR) is a receptor tyrosine kinase that 
instructs key cellular programs such as proliferation, survival, 
and locomotion. The implementation of these programs requires 
EGFR signals to be of defined strength within precise boundar-
ies of space and time. While spurious EGFR activation is to be 
avoided, preventing excess EGFR activity is also crucial be-
cause the latter disrupts tissue homeostasis and may lead to cell 
transformation (Sibilia et al., 2007).
Inadvertent activation of EGFR is prevented by self- 
inhibitory constraints imposed on both the extracellular ligand-
binding region (Burgess et al., 2003) and the intracellular 
catalytic domain of the receptor (Zhang et al., 2006). Ligand 
binding relieves these constraints by driving dimerization of 
EGFR extracellular domains (Burgess et al., 2003). This is con-
ducive to the formation of asymmetric dimers between juxta-
posed kinase domains, allowing for allosteric activation of the 
kinase, receptor auto-phosphorylation, and initiation of down-
stream signaling (X. Zhang et al., 2007). EGFR signaling is in 
turn subject to the close control of negative regulatory circuits. 
Among these, a prominent role is played by (a) receptor endo-
cytosis,  which  leads  to  fast  internalization  of  ligand–EGFR 
complexes (Sorkin and Goh, 2009); and (b) a network of induc-
ible inhibitors that target several pathway components, includ-
ing the EGFR itself, in order to ensure tight control of EGFR 
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ignaling  by  epidermal  growth  factor  receptor 
(EGFR)  must  be  controlled  tightly  because  aber-
rant EGFR activity may cause cell transformation. 
Receptor-associated late transducer (RALT) is a feedback 
inhibitor of EGFR whose genetic ablation in the mouse 
causes phenotypes due to EGFR-driven excess cell prolifera-
tion. RALT inhibits EGFR catalytic activation by docking 
onto EGFR kinase domain. We report here an additional 
mechanism  of  EGFR  suppression  mediated  by  RALT, 
demonstrating that RALT-bound EGF receptors undergo 
endocytosis and eventual degradation into lysosomes. 
Moreover,  RALT  rescues  the  endocytic  deficit  of EGFR 
mutants unable to undergo either endocytosis (Dc214) or 
degradation (Y1045F) and mediates endocytosis via a 
domain distinct from that responsible for EGFR catalytic 
suppression.  Consistent  with  providing  a  scaffolding 
function for endocytic proteins, RALT drives EGFR endo-
cytosis by binding to AP-2 and Intersectins. These data 
suggest a model in which binding of RALT to EGFR inte-
grates suppression of EGFR kinase with receptor endo-
cytosis and degradation, leading to durable repression 
of EGFR signaling.
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Results
RALT-bound EGFR undergoes  
efficient endocytosis
We engineered stable NR6-EGFR cells in which ectopic RALT 
inhibited EGFR kinase activity by >90% and mimicked the 
pharmacological suppression of EGFR kinase activity observed 
in control NR6-EGFR cells upon treatment with the EGFR- 
specific inhibitor AG1478 (Fig. 1 A). This cellular model is 
therefore suitable for quantitative biochemical studies of EGFR 
endocytosis under two different conditions of virtually com-
plete suppression of EGFR catalytic activity.
Cell  imaging  studies  indicated  that AG1478  ablated   
ligand-dependent  EGFR  internalization  in  NR6-EGFR  cells.   
In contrast, a rapid relocalization of EGFR to intracellular vesi-
cles was observed in EGF-treated NR6-EGFR/RALT cells,   
irrespective of AG1478 (Fig. S1 A). Initial rates of [
125I]-EGF 
uptake were comparable in NR6-EGFR/RALT and control cells 
(Fig. 1 B), with internalization rate constants (Ke; see Materials 
and methods) being 0.184 ± 0.023 and 0.189 ± 0.029, respec-
tively. In contrast, AG1478 led to a dramatic reduction of [
125I]-EGF 
uptake in NR6-EGFR cells, as reported previously (Sorkina 
et al., 2002; Fig. 1 B). EGF-driven endocytosis caused extensive   
down-regulation (Fig. 1 C) and eventual degradation (Fig. 1 D) 
of EGFR in both control and NR6-EGFR/RALT cells. This was 
not observed in NR6-EGFR cells treated with the EGF + 
AG1478 combination (Fig. 1 C; Fig. S1 B). Finally, EGFR   
and RALT colocalized in vesicular structures labeled by the 
early (EEA1) and late (LAMP1) endosome markers (Fig. 1 E), 
indicating that the endocytic traffic of EGFR in NR6-EGFR/
RALT cells was associated to sustained EGFR–RALT physi-
cal interaction and uninterrupted suppression of EGFR cata-
lytic function.
RALT rescues the endocytic deficit of 
EGFR Dc214
How  can  RALT-bound  EGFR  molecules  undergo  efficient 
endocytosis and degradation despite being catalytically inert? 
We reasoned that RALT itself could form a platform for molec-
ular interactions capable of organizing EGFR endocytic traffic. 
To test this hypothesis we focused on EGFR Dc214, a catalyti-
cally competent EGFR mutant that lacks the C-tail and is there-
fore unable to couple to canonical EGFR endocytic pathways 
(Chen et al., 1989). EGFR Dc214 retains RALT binding (Anastasi   
et al., 2003, 2007) and underwent ligand-dependent endocytosis 
in serum-starved cells expressing ectopic RALT, but not in con-
trol NR6-EGFR Dc214 fibroblasts (Fig. 2 A). Colocalization 
studies indicated that internalized EGFR Dc214 was routed to 
early endosomes in complex with RALT (Fig. 2 B). We next ad-
dressed whether endogenous levels of RALT protein were suffi-
cient  to  signal  endocytosis  of  EGFR  Dc214. To  this  end, 
NR6-EGFR Dc214 cells were rendered quiescent by serum   
deprivation and subsequently stimulated with 10% serum for 3 h   
to induce robust expression of RALT protein (Fig. 2, C and D; 
see also Fiorentino et al., 2000). After serum wash-out, cells 
were challenged with EGF for 10 min at 37°C. Serum stimula-
tion alone did not induce EGFR Dc214 endocytosis, which was 
signaling over timescales of several hours (Amit et al., 2007; 
Fry et al., 2009).
RALT (receptor-associated late transducer; also known as 
MIG6  and  ERRFI1)  is  a  transcriptionally  induced  feedback   
inhibitor of EGFR (Anastasi et al., 2005; Xu et al., 2005). 
Increased RALT dosage suppresses EGFR signaling in in vitro 
cell-based assays (Hackel et al., 2001; Anastasi et al., 2003; Xu 
et al., 2005) and in mouse tissues such as skin and myocardium 
(Ballarò et al., 2005; Cai et al., 2009). Silencing of RALT in 
cultured cells enhances cellular responses induced by EGFR 
activation (Anastasi et al., 2005; Reschke et al., 2009). More-
over, Errfi1
/ mice display a fully penetrant skin phenotype, 
showing increased thickness of the epidermis, altered cellular 
differentiation, and enhanced susceptibility to cancerogenesis 
due to excess EGFR activity and attendant hyper-proliferation 
of keratinocytes (Ferby et al., 2006).
An important question concerns the identification of the 
molecular mechanism(s) through which RALT exerts its essen-
tial role of EGFR inhibitor and putative tumor suppressor func-
tion (Anastasi et al., 2005; Ferby et al., 2006; Y.W. Zhang et al., 
2007). Previous studies have demonstrated that RALT inhibits 
EGFR catalytic activation by binding to ligand-engaged EGFRs 
via its ErbB binding region (EBR; Xu et al., 2005; Anastasi   
et al., 2007). In detail, RALT binds to the dimer interface   
located in the distal portion of the C-terminal lobe of the EGFR 
kinase domain, thus precluding formation of asymmetric kinase 
dimers and locking the EGFR kinase in a catalytically unproduc-
tive configuration (X. Zhang et al., 2007).
Earlier work had also shown that cytoplasmic RALT re-
localizes to internalized EGFR (Anastasi et al., 2003). This creates   
a conundrum because sustained catalytic activation of the EGFR 
is held as a sine qua non for its ligand-dependent endocytic traffic 
(Sorkin and Goh, 2009). For example, sorting of ligand-activated 
EGFR into clathrin-coated pits (CCPs) requires binding of GRB2 
to auto-phosphorylated EGFR (Jiang et al., 2003; Huang and 
Sorkin, 2005; Johannessen et al., 2006) and is prevented by phar-
macological inhibition of the EGFR kinase (Sorkina et al., 2002). 
Catalytic activation of EGFR is also necessary for EGFR–CBL 
complex formation and CBL-dependent ubiquitylation of EGFR 
(Levkowitz et al., 1998, 1999). Ubiquitylation plays an obliga-
tory role in routing internalized EGFR molecules into multi-
vesicular bodies (MVBs), a step that terminates EGFR signaling 
and targets the receptor for destruction into lysosomes (Sorkin 
and Goh, 2009). Thus, through the kinase-dependent regulation 
of its own phosphorylation and ubiquitylation, activated EGFR 
nucleates protein–protein interactions capable of promoting its 
endocytic traffic from the plasma membrane to late endosomes.
Herein, we address whether RALT-bound EGFR mole-
cules are capable of undergoing endocytosis. We find that RALT 
is capable of driving the internalization and eventual degrada-
tion of EGFR molecules that are neither tyrosine phosphory-
lated nor ubiquitylated. We ascribe the pro-endocytic activity of 
RALT to its ability of scaffolding endocytic proteins and pro-
pose that RALT ensures durable attenuation of EGFR signaling 
by integrating two mechanisms so far considered to be mutually 
exclusive, namely suppression of EGFR catalytic activity and 
receptor down-regulation.559 RALT/MIG6 drives kinase-inactive EGFR endocytosis • Frosi et al.
Figure 1.  Kinase inhibition by RALT, but not by AG1478, is associated to normal rates of EGFR endocytosis and down-regulation. (A) Expression of EGFR 
and MYC-RALT was reconstituted in NR6 fibroblasts, which lack endogenous EGFR expression. Control and RALT-overexpressing NR6-EGFR cells were 
rendered quiescent and then stimulated with 100 ng/ml EGF (±3 µM AG1478) for the indicated time. Lysates were immunoblotted as indicated. (B) Con-
trol (±3 µM AG1478) and MYC-RALT–expressing NR6-EGFR cells were assayed for [
125I]-EGF uptake (1 ng/ml at 37°C for the indicated time). The graph 
reports the average results ± SD from four independent experiments. (C) Control (±3 µM AG1478) and MYC-RALT–expressing NR6-EGFR cells were made 
quiescent, incubated at 37°C with 100 ng/ml EGF for the indicated time, and processed to determine residual [
125I]-EGF binding at the cell surface (per-
centage of binding at time 0). Results were averaged from three independent experiments ± SD. (D) EGFR degradation. Control and MYC-RALT–expressing 
NR6-EGFR cells were rendered quiescent and then stimulated with 100 ng/ml EGF for the indicated time (hours). Lysates were immunoblotted with the 
indicated antibodies. Two different exposures of the same anti-EGFR autoradiograph are shown. (E) Quiescent MYC-RALT–expressing NR6-EGFR cells were 
incubated with 20 ng/ml EGF on ice for 30 min. After EGF wash-out, cells were chased at 37°C in EGF-free medium for either 10 min (for EGFR/EEA1 
and EGFR/RALT colocalization) or 30 min (for EGFR/LAMP-1 colocalization). Nuclei were stained with Hoechst 33258 (blue). Bar, 5 µm.JCB • VOLUME 189 • NUMBER 3 • 2010   560
Figure 2.  RALT rescues the endocytic deficit of EGFR Dc214. (A) Quiescent control and MYC-RALT–expressing NR6-EGFR Dc214 cells were either left 
untreated or stimulated with 20 ng/ml EGF for 10 min at 37°C. Cells were fixed and stained with anti-EGFR mAb 108 (red) and Hoechst 33258 (blue). 
(B) MYC-RALT–expressing NR6-EGFR Dc214 cells were rendered quiescent and then incubated with 20 ng/ml EGF on ice for 30 min. After EGF wash-out, 
cells were chased at 37°C in EGF-free medium for 10 min, fixed, and stained for EGFR, EEA1, and MYC-RALT immunodetection. Nuclei were stained with 
Hoechst 33258 (blue). (C) NR6-EGFR Dc214 cells were transfected with either control or RALT-specific siRNAs. Cells were made quiescent by serum depri-
vation and then challenged with 10% newborn calf serum (NCS) for 3 h to induce RALT protein expression. After serum wash-out, cells were left untreated 
or stimulated with 20 ng/ml EGF for 10 min at 37°C before being processed for anti-EGFR staining (red). Nuclei were stained with Hoechst 33258 (blue).   
Sister cultures were lysed to monitor the efficiency of RALT KD by immunoblot (top). Nontransfected NR6-EGFR Dc214 cells (±NCS stimulation) were in-
cluded as additional immunoblotting controls. -Actin was used as loading control. (D) Control and RALT siRNA-transfected NR6 Dc214 cells were made 
quiescent and then stimulated with NCS as in C. After serum wash-out, cells were incubated with 1 ng/ml [
125I]-EGF for 8 min at 37°C. Nontransfected 
cells (±NCS stimulation) were included as additional control. Columns report the average of three independent experiments ± SD. Bars: (A and C) 20 µm; 
(B) 5 µm.561 RALT/MIG6 drives kinase-inactive EGFR endocytosis • Frosi et al.
namely  RALT Y358A  (X.  Zhang  et  al.,  2007)  and  RALT 
315-361 (Anastasi et al., 2007), did not support endocyto-
sis of EGFR Dc214 (Fig. 3, A and B; expression levels of 
MYC-tagged RALT proteins are shown in Fig. S2 A). These 
results suggest that binding to EGFR is necessary but not suffi-
cient for RALT-mediated endocytosis. Indeed, overexpressed 
RALT282–396, but not RALT Y358A, displayed dominant-negative 
activity toward endogenous RALT in EGFR Dc214 internaliza-
tion assays (Fig. 3, C and D), most likely because it prevented 
recruitment of endogenous RALT to EGFR Dc214.
Based on the above results, we hypothesized that reloca-
tion of RALT onto the EGFR via the EBR enables structural   
determinants of RALT distinct from the EBR itself to be con-
nected to the endocytic machinery. This model predicts that 
RALT should mediate endocytosis independently of its EBR 
when placed in cis to EGFR1–682, namely to an EGFR lacking 
both the kinase domain and C-terminal tail (Fig. 4 A). The 144–
411 fragment of RALT spans the evolutionarily conserved re-
gion of the protein (Anastasi et al., 2007) and was capable of 
driving efficient down-regulation of EGFR Dc214 (Fig. S2 B). 
Strikingly, a chimera spanning the RALT 144–411 fragment 
fused to the C-terminal end of EGFR1–682 (ER144–411) underwent 
rapid endocytosis when expressed in NR6 cells (Fig. 4 B). 
instead observed in cells exposed to the EGF pulse (Fig. 2 C). 
Crucially,  endocytosis  of  EGFR  Dc214  was  abrogated  by 
knock-down (KD) of RALT (Fig. 2 C). [
125I]-EGF uptake as-
sayed in the same conditions confirmed that RALT-specific 
RNAi reduced EGFR Dc214 endocytosis to background levels 
(Fig. 2 D). Of note, RALT KD altered neither transferrin uptake 
in serum-stimulated NR6-EGFR Dc214 cells (Fig. S1 C) nor 
wtEGFR  endocytosis  in  serum-stimulated  NR6-EGFR  cells 
(Fig. S1, D and E). We conclude that RALT KD does not cause 
a general disruption of endocytosis and that under physiological 
conditions RALT-bound and RALT-free EGFR molecules are 
internalized with comparable efficiency.
Identification of an endocytic domain in the 
RALT protein
To identify the structural determinants of RALT required for 
RALT-mediated endocytosis we focused initially on the region 
that contacts the EGFR kinase domain, namely the EBR module 
that spans positions 323–411 (X. Zhang et al., 2007). Because 
we could not express RALT323–411 in NR6-Dc214 cells at suitable 
levels, we resorted to using RALT282–396, which we showed was 
sufficient to suppress EGFR kinase activity (Anastasi et al., 2007). 
RALT282–396, as well as two mutants unable to bind to EGFR, 
Figure 3.  Relocation onto EGFR is required for RALT-mediated endocytosis. (A and B) Quiescent NR6-EGFR Dc214 cells expressing the indicated MYC-
RALT alleles were assayed for [
125I]-EGF uptake (1 ng/ml at 37°C for the indicated time). The graphs report average results ± SD from four (A) and three (B)   
independent experiments. (C and D) NR6-EGFR Dc214 cells expressing the indicated MYC-RALT alleles were made quiescent and then assayed for 
[
125I]-EGF uptake (1 ng/ml for 8 min at 37°C) either before or after a 3-h stimulation with 10% NCS to induce RALT expression. Results were averaged ± SD 
from three independent experiments. Comparison between endogenous and ectopic RALT proteins indicates that the latter are largely overexpressed (see 
Fig. S2 A), thus allowing the assessment of their potential dominant-negative activity over endogenous RALT.JCB • VOLUME 189 • NUMBER 3 • 2010   562
To assess whether the endocytosis of the RED-containing 
chimera was still EGF inducible, we used as endocytic tracer 
the mAb 108, which recognizes the EGFR extracellular domain 
independently of EGF binding (see Materials and methods). 
Results presented in Fig. 4 C show that mAb 108 was internal-
ized in NR6 cells expressing the ER144–323 chimera irrespective 
The EBR-containing chimera (ER323–411) behaved similarly 
to EGFR1–682 and was not internalized. The endocytic determi-
nants of RALT were mapped to the RALT144–323 fragment be-
cause the ER144–323 chimera was internalized as efficiently as 
ER144–411 (Fig. 4 B). Thus, the RALT 144–323 fragment was 
named RED (RALT endocytic domain).
Figure 4.  Identification of the RALT endocytic domain. 
(A) Schematic representation of chimeras generated by fus-
ing the indicated fragments of RALT to the C-terminal end of 
EGFR1–682. (B) The indicated EGFR1–682-RALT chimeras (referred 
to as ER, see panel A) were expressed in NR6 cells. Quiescent 
cells were assayed for [
125I]-EGF uptake (3 ng/ml for 5 min 
at 37°C). Columns report average results ± SD from four   
independent experiments. (C) Quiescent NR6 cells expressing 
either wt EGFR or ER144–323 were allowed to bind mAb 108 
(3 µg/ml) for 30 min on ice either in the absence or presence 
of EGF (20 ng/ml). After mAb wash-out, cells were shifted to 
37°C in mAb/EGF-free medium for 10 min. After fixation, 
cells were stained with anti–mouse IgG to visualize mAb 108 
(red) and Hoechst 33258 (blue). (D) Quiescent NR6-ER144–323 
cells were incubated for 30 min on ice with 3 µg/ml mAb 
108.  After  mAb  wash  out,  cells  were  chased  for  10  min 
at 37°C in serum-free medium before being processed for   
mAb 108 and EEA1 immuno-imaging. Nuclei were stained 
with Hoechst 33258 (blue). Bars: (C) 20 µm; (D) 5 µm.563 RALT/MIG6 drives kinase-inactive EGFR endocytosis • Frosi et al.
RALT couples the EGFR to clathrin-
dependent endocytosis via AP-2
Several  mechanisms  of  internalization  were  discovered  for 
EGFR (Orth and McNiven, 2006; Acconcia et al., 2009; Sorkin 
and Goh, 2009). RALT colocalized with clathrin heavy chain 
(CHC) upon EGF stimulation (Fig. 6 A). CHC KD in NR6-
EGFR Dc214 cells abolished [
125I]-transferrin uptake as well 
as RALT-mediated uptake of [
125I]-EGF (Fig. 6 B). In keeping 
with  these  results,  RALT-dependent  endocytosis  of  EGFR 
Dc214 required dynamin2, a GTPase implicated in the forma-
tion  and  fission  of  clathrin-coated  structures  at  the  plasma 
membrane (Macia et al., 2006; Loerke et al., 2009), as shown 
by the inhibitory activity exerted by both K44A DYN2, a 
dominant-negative dynamin2 mutant, and dynasore, a revers-
ible inhibitor of dynamin GTPase activity (Macia et al., 2006; 
Fig. 6, C and D).
AP-2 is the major adaptor complex involved in CME and 
binding to AP-2 allows cargos to be sorted into CCPs (Traub, 
2009). Depletion of the 2 chain of the AP-2 complex resulted 
in marked inhibition of RALT-dependent endocytosis of EGFR 
Dc214. This effect was proportional to the extent of 2 deple-
tion as determined by two different siRNAs (Fig. 6 E). Purified 
recombinant GST-RALT145–414 immobilized onto agarose beads 
was able to bind to AP-2 present in cell lysates, as assessed by 
immunoblotting with antibodies to 2 and 2 chains of AP-2, 
whereas RALT325–414 did not (Fig. S4 A). Hence, binding of 
RED to AP-2 may sort EGFR–RALT complexes into CCPs.
Role of Intersectin in RALT-dependent 
endocytosis
A number of endocytic proteins, including several accessory 
proteins, contain one or more Src homology 3 (SH3) domains 
(Simpson et al., 1999; Praefcke et al., 2004). We have previ-
ously shown that RALT binds to SH3 domains, with most of the 
SH3-binding  motifs  being  located  in  the  144–323  sequence 
(Fiorentino  et  al.,  2000).  We  therefore  sought  to  determine 
whether RALT couples to SH3-containing proteins implicated 
in endocytic traffic. By combining computational predictions 
and literature-generated hypotheses we restricted our attention 
to SH3 domains present in 20 mammalian proteins. GST pull-
down  assays  indicated  that  recombinant  SH3  domains  from 
GRB2, PIX/Cool1, Intersectin1, and Intersectin2 (mammals 
express  two  ITSN  isoforms  encoded  by  distinct  loci;  see 
Pucharcos et al., 2001) bound RALT with the highest affinity 
(Fig. S4 B). We used RNAi to test whether the loss of GRB2, 
PIX, or ITSNs impacts RALT-mediated endocytosis. Although 
GRB2 and PIX are dispensable for RALT-driven endocytosis 
of EGFR Dc214 (Fig. S4, C and D), ITSN function appears to 
be necessary. In particular, the KD of ITSN2 reduced EGFR 
Dc214 endocytosis by 40% (Fig. 7 A). RNAi to ITSN1 pro-
duced a minor, albeit reproducible, reduction of EGFR Dc214 
internalization, which was additive to the effect of RNAi to 
ITSN2 in combined ITSN1 + ITSN2 KD experiments (Fig. 7 A). 
ITSN2 KD had no consequence on the endocytosis of wtEGFR 
(Fig. S4 E), which was instead compromised by GRB2 KD, as 
reported previously (Jiang et al., 2003; Fig. S4 C). Thus, RALT-
dependent and RALT-independent endocytosis of EGFR have 
of EGF stimulation and was routed to the endosomal compart-
ment (Fig. 4 D). This constitutive internalization is specific   
because the intracellular accumulation of mAb 108 in NR6-
EGFR cells was strictly dependent on EGF stimulation.
The experiments presented in Figs. 3 and 4 indicate that 
kinase suppression and endocytic activity are genetically sepa-
rable functions of RALT that map to two distinct modules, i.e., 
the EBR and RED, respectively.
RALT signals degradation of EGFR
Internalized EGFR can either be recycled to the cell surface or 
further trafficked to lysosomes for degradation. While recycling 
favors reiteration of EGFR signaling (Lenferink et al., 1998;   
Sigismund et al., 2008), sorting into MVBs terminates it and, by 
causing receptor degradation, also attenuates the cell’s respon-
siveness to further stimulation by EGFR ligands (Marmor and 
Yarden, 2004).
As shown before, RALT-bound EGFR molecules undergo 
down-regulation and degradation (Fig. 1, C and D). RALT also 
promoted down-regulation (Fig. 5 A and Fig. S2 C) and degra-
dation  of  EGFR  Dc214,  as  extrapolated  by  the  observation   
that a sizeable amount of input [
125I]-EGF underwent degrada-
tion in NR6-EGFR Dc214/RALT cells (Fig. 5 B and Fig. S2 D). 
Consistently, EGFR Dc214–RALT complexes trafficked to 
anti-LAMP1–labeled endosomes (Fig. 5 C). Thus, besides 
rescuing the internalization deficit of EGFR Dc214, RALT   
was also capable of routing internalized EGFR Dc214 to 
late endosomes.
Trafficking toward the MVBs and consequent lysosomal 
degradation depend on CBL-driven EGFR ubiquitylation. The 
EGFR Y1045F mutant lacks the phosphotyrosine binding site 
for CBL. As a consequence, EGFR Y1045F is ubiquitylated 
poorly and is recycled to the cell surface rather than being sorted 
into MVBs/late endosomes (Levkowitz et al., 1999). Strikingly, 
RALT overexpression rescued the degradation deficit of EGFR 
Y1045F. Comparable results were obtained when the expres-
sion of EGFR Y1045F and RALT was reconstituted either sta-
bly in NR6 fibroblasts (Fig. 5 D) or transiently in CHO epithelial 
cells (Fig. S3 A). Notably, RALT-driven degradation of EGFR 
Y1045F was inhibited in cells treated with chloroquine (Fig. 5 D), 
pointing to lysosomes as the site of RALT-dependent degrada-
tion of EGFR. Neither RALT282–396 (Fig. S3 A) nor RALT323–411 
(Fig. S3 B) was capable of rescuing the degradation deficit   
of EGFR Y1045F. In contrast, RALT144–411 induced degradation 
of both wtEGFR (Fig. S2 E) and EGFR Y1045F (Fig. S3 B). 
Thus, the RED mediates internalization as well as degradation 
of EGFR.
The  ubiquitylation  deficit  imposed  on  EGFR  by  the 
Y1045F mutation was not rescued by the ectopic expression of 
RALT (Fig. 5 E). This is consistent with the notion that binding 
of  CBL  to  the  EGFR  requires  receptor  autophosphorylation 
(Levkowitz et al., 1998, 1999), which is abolished by RALT-
mediated kinase inhibition. Indeed, also in the case of wtEGFR, 
RALT inhibited recruitment of CBL to the receptor as well as 
EGFR ubiquitylation (Fig. S3 C). The above data indicate that 
RALT-bound EGFR molecules undergo degradation into lyso-
somes in the absence of receptor ubiquitylation.JCB • VOLUME 189 • NUMBER 3 • 2010   564
Figure 5.  RALT drives degradation of EGFR Dc214 and EGFR Y1045F. (A) EGFR Dc214 down-regulation. Control and MYC-RALT–expressing NR6-EGFR 
Dc214 cells were made quiescent and assayed for receptor down-regulation as in Fig. 1 C. Graphs indicate the average results ± SD from three inde-
pendent experiments. (B) [
125I]-EGF degradation. Quiescent control and MYC-RALT–expressing NR6-EGFR Dc214 cells were allowed to bind [
125I]-EGF 
on ice (15 ng/ml for 45 min). After washing, cells were shifted to 37°C in EGF-free medium for the indicated time. Degraded [
125I]-EGF was measured 
as the fraction of TCA-soluble radioactivity (i.e., the sum of TCA-soluble cpm measured in cell lysates and extracellular medium) over bound [
125I]-EGF. 
Results were averaged (±SD) from three independent experiments. Note that under these conditions EGF stimulation induces significant RALT expression 
in control NR6-EGFR Dc214 cells by 90 min (not depicted), which likely explains why in control cells [
125I]-EGF degradation increases above background 
past the 1.5-h time point. (C) Quiescent MYC-RALT–expressing NR6-EGFR Dc214 cells were incubated with EGF on ice as in Fig. 2 B, washed, chased in   
EGF-free medium for 30 min at 37°C, and processed for EGFR, LAMP-1, and MYC-RALT immuno-imaging. Nuclei were stained by Hoechst 33258.   
(D) Top: control and MYC-RALT–expressing NR6-EGFR Y1045F cells were made quiescent and then stimulated with 100 ng/ml EGF for the indicated 
time. Where indicated, chloroquine was added to the culture medium throughout the EGF incubation time. Lysates were immunoblotted with the indicated 
antibodies. Two different exposures of the same anti-EGFR autoradiograph are shown. Bottom: sister plates were stimulated with 100 ng/ml EGF for 
5 min at 37°C to document the extent of catalytic suppression of EGFR Y1045F by MYC-RALT. Blots were probed as indicated; AKT was used as 
loading control. (E) NR6 fibroblasts expressing either wtEGFR or EGFR Y1045F in the absence (Ctrl) or presence of ectopic MYC-RALT (RALT) were made 
quiescent and either left untreated or incubated with 20 ng/ml EGF for the indicated time (min). Anti-EGFR immunoprecipitates and total cell lysates were 
immunoblotted as indicated. Bar, 5 µm.565 RALT/MIG6 drives kinase-inactive EGFR endocytosis • Frosi et al.
Figure 6.  RALT-mediated endocytosis is clathrin- and AP-2–dependent. (A) MYC-RALT–expressing HeLa cells were made quiescent and then incubated 
with 20 ng/ml EGF for 5 min at 37°C before MYC-RALT and CHC immunostaining. (B) NR6-EGFR Dc214 RALT cells were transfected with control and 
CHC-specific siRNAs. Cells were rendered quiescent and assayed for [
125I]-EGF (1 ng/ml for 6 min at 37°C) and [
125I]-Tf (0.5 µg/ml for 4 min at 37°C) 
uptake. Results were averaged ± SD from four independent experiments. The immunoblot documents the typical efficiency of CHC KD; -actin was used as 
loading control. (C) CHO cells were transfected with either GFP or dominant-negative (DN) DYN2 K44A-GFP vectors along with either pcDNA3-EGFR + 
pCS2MT (left) or pcDNA3-EGFR Dc214 + pCS2MT-RALT (right). 2 d after transfection, cells were made quiescent and stimulated with 20 ng/ml EGF for 
10 min at 37°C before being processed for anti-EGFR staining. Nuclei were stained with Hoechst 33258 (blue). (D) Quiescent NR6-EGFR Dc214 cells were 
incubated for 30 min at 37°C with either vehicle or 80 µM dynasore before being assayed for [
125I]-EGF uptake (± dynasore) for 6 min at 37°C. Results 
were averaged ± SD from three independent experiments. (E) NR6-EGFR Dc214 cells were transfected with control and two different 2-specific siRNAs. 
Cells were made quiescent and assayed for [
125I]-EGF uptake (1 ng/ml for the indicated time at 37°C). Results were averaged ± SD from three independent 
experiments. The immunoblot documents 2 KD, which causes also concomitant reduction of the 2 subunit, as reported previously (Johannessen et al., 
2006); CHC was used as loading control. Bars, (A) 10 µm; (inset) 5 µm; (C) 20 µm.JCB • VOLUME 189 • NUMBER 3 • 2010   566
located coiled-coil region, and five SH3 domains (denominated 
A through E; O’Bryan et al., 2001). RALT bound in vitro to 
SH3 A, C, and E of ITSN (Fig. S5 A) and coimmunoprecipi-
tated specifically with a fragment of ITSN spanning the five 
differential requirements for GRB2 and ITSN2 function, at least 
in NR6 fibroblasts.
The prevalent isoforms of ITSN1 and ITSN2 have a   
modular architecture consisting of two EH domains, a centrally 
Figure 7.  ITSN recruitment by RALT is necessary for RALT-mediated endocytosis. (A) NR6-EGFR Dc214 cells were transfected with either control or ITSN-
specific siRNAs. Cells were made quiescent before being tested for [
125I]-EGF uptake (1 ng/ml for the indicated time at 37°C). An experiment representative 
of three independent experiments is shown. ITSN KD efficiency was documented by immunoblot (ITSN1, bottom) and RT-PCR (ITSN2, top; note that our 
anti-ITSN2 antibody does not react against the mouse protein). GAPDH was used as RT-PCR reaction control. (B and C) HEK 293 cells were transfected 
with either empty vector (Ctrl) or vectors directing the expression of the indicated EGFR1–682-RALT chimeras. Lysates were subjected to immunoprecipitation   
with anti-EGFR mAb 108 (B) and anti-ITSN2 antiserum (C). Total cell lysates (TCL, 5% of input lysate in IPs) and IPs were immunoblotted as indicated. 
(D) HEK 293 cells were cotransfected with vectors encoding HA-tagged 5SH3 X. laevis ITSN and the indicated MYC-RALT alleles. Cell lysates were immuno-
precipitated with anti-HA antibodies and immunoblotted with anti-MYC 9E10 mAb. (E) EGFR Dc214 cells expressing comparable amounts of either wt or 
MYC-RALT 4Ala (see immunoblot) were made quiescent and assayed for [
125I]-EGF uptake (1 ng/ml at 37°C). Columns report the endocytic rate constants 
Ke averaged from three independent experiments (0.131 ± 0.006 for wtRALT and 0.099 ± 0.013 for RALT 4Ala, P = 0.039).567 RALT/MIG6 drives kinase-inactive EGFR endocytosis • Frosi et al.
Our results clearly show that RALT-dependent endocyto-
sis of EGFR is clathrin- and AP-2–dependent. RALT binds to 
the AP-2 complex and we suggest that this interaction is key to 
sorting EGFR–RALT complexes into CCPs. Binding of RALT 
to AP-2 requires determinants located within the RED. Two 
evolutionarily  conserved  sequences  are  present  in  the  RED, 
namely  178DTDFLL183 (which fits well with the [DE]XXXL[LIM] 
consensus for binding to the :2 hemi-complex of AP-2) and 
209YAYF212 (conforming to the YXX consensus for binding   
to the 2 chain of AP-2; Traub, 2009). Further experiments   
are needed to evaluate their possible involvement in the RALT–
AP-2 interaction.
RALT interacts functionally and physically with the ac-
cessory proteins ITSN1 and ITSN2, which are thought to be 
important for promoting maturation of cargo-loaded CCPs 
(Mettlen et al., 2009). ITSNs scaffold several components of the 
endocytic machinery, including AP-2 (Praefcke et al., 2004; 
Schmid et al., 2006), Epsin, EPS15 (Sengar et al., 1999), dyna-
min (Yamabhai et al., 1998), CIN85 (Nikolaienko et al., 2009), 
and CBL (Martin et al., 2006). The ITSN–RALT interaction is 
mediated by the SH3 domains of ITSNs and Pro-rich sequences 
located in the RED. As proved by RNAi experiments, ITSN1 
and ITSN2 serve nonredundant functions in RALT-dependent 
endocytosis, with ITSN2 playing a prevalent role. Inhibiting the 
RALT–ITSNs interaction by the 4Ala mutation was likewise 
effective in reducing the rate of EGFR Dc214 endocytosis, sup-
porting the notion that the RALT–ITSNs physical interaction is 
required for RALT-dependent CME.
The remarkable requirement of RALT-driven endocytosis 
for ITSN2 highlights mechanistic differences between the CME 
of kinase-active EGFR, which was insensitive to ITSN2 KD, 
and that of EGFR–RALT complexes. RALT-bound EGFR mol-
ecules lack ubiquitylation and are therefore unable to recruit ac-
cessory  proteins  containing  ubiquitin-interacting  motifs,  i.e., 
EPS15, Epsin, and EPS15R (Traub, 2009). RALT may alleviate 
this deficit by recruiting ITSNs via SH3-directed interactions 
and we propose that ITSNs, as accessory protein recruited di-
rectly by RALT, could play a major role in driving the matura-
tion of CCPs loaded with EGFR–RALT complexes (Mettlen 
et al., 2009). Given their ability to engage in multivalent inter-
action with the 2 and 2 subunit of the AP-2 complex, ITSNs 
have been proposed to function also as accessory cargo adaptors 
(Schmid et al., 2006) and could therefore enhance AP-2– 
dependent sorting of EGFR–RALT complexes into nascent CCPs. 
Our results also raise the issue of why ITSN2 has a prevalent 
role over ITSN1 in RALT-mediated endocytosis. This may be 
explained by the higher affinity of ITSN2 SH3 domains for 
RALT (Fig. S5 D). The long isoforms (ITSN-L) of ITSNs also 
couple endocytosis to actin remodelling (Hussain et al., 2001; 
McGavin et al., 2001). Whereas ITSN1-L is restricted to neuro-
nal cells, ITSN2-L is expressed ubiquitously (Pucharcos et al., 
2001). Thus, in nonneuronal cells, ITSN2-L could contribute a 
signaling function crucial to RALT-dependent endocytosis.
The RED is also required for directing EGFR into late 
endosomes  independently  of  EGFR  ubiquitylation.  Our  results 
show that RALT rescues the degradation, but not the ubiqui-
tylation, deficit of EGFR Y1045F. This finding underscores 
SH3 domains (Fig. S5 B). Binding of RALT to ITSN required 
the RED: GST-RALT145–414, but not GST-RALT325–414, precipi-
tated endogenous ITSN1 and ITSN2 from cell lysates (Fig. S5 C). 
Moreover, endogenous ITSN1 and ITSN2 coimmunoprecipitated 
only with the ER144–323 chimera in mAb 108 immunoprecipita-
tions (Fig. 7 B); reciprocally, anti-ITSN2 antibodies brought 
down ER144–323 (Fig. 7 C).
SH3 domains recognize a PXXP core sequence flanked by 
a positively charged amino acid (+) in either class I (+XXPXXP) 
or class II (PXXPX+) orientation (Mayer, 2001). Several PXXP 
sequences are clustered within the RED between positions 278 
and 322. Based on the probability score assigned by the Scan-
site program (http://scansite.mit.edu) to candidate ITSN bind-
ing  motifs  in  RALT,  we  introduced Ala  substitutions  in  the 
279PEIPPR284 and 315PKVPPR320 RALT sequences (underlined 
residues were changed to A). As shown in Fig. 7 D, RALT lost 
the ability to coimmunoprecipitate with a recombinant protein 
spanning the five SH3 domains of XlITSN when both of the 
above PXXPXR sequences were mutated (RALT 4Ala). GST-
5SH3 recombinant proteins from either ITSN1 or ITSN2 lost 
the ability to interact with RALT 4Ala (Fig. S5 D). Finally, the 
4Ala  mutation  strongly  reduced  the  interaction  between  the 
ER144–323  chimera  and  ITSNs  (Fig.  7,  B  and  C).  Strikingly, 
RALT 4Ala showed a significant reduction in the ability of driv-
ing  EGFR  endocytosis  as  measured  by  [
125I]-EGF  uptake   
(Fig. 7 E; Fig. S5 E). We note that combined RNAi to ITSN1 
and ITSN2 had a stronger effect than the 4Ala mutation on 
EGFR Dc214 endocytosis, possibly because 4Ala mutants dis-
played some residual binding to ITSNs (Fig. 7, B–D).
The sum of the above results supports a model whereby 
the endocytic domain of RALT couples EGFR to CME via its 
interaction with AP-2 and Intersectins.
Discussion
Ligand-activated EGFR drives its own endocytic traffic by inter-
acting with endocytic proteins. This network of protein–protein 
interactions is activated by post-translational modifications of 
the EGFR, i.e., tyrosine phosphorylation and ubiquitylation, 
which are induced and maintained by EGFR kinase activity. 
Hence, EGFR endocytic traffic is intimately connected to recep-
tor activation (Sorkin and Goh, 2009). Deviating from this con-
solidated notion, we show here that RALT-bound EGFR molecules 
are internalized and eventually delivered to lysosomes for degra-
dation in the absence of EGFR kinase activity.
RALT rescues the endocytic deficit of EGFR mutants un-
able to undergo either internalization (EGFR Dc214) or sorting 
from early endosomes into MVBs (EGFR Y1045F). The endo-
cytic activities of RALT map to the 144–323 sequence, which 
we called RED. The isolated EBR domain phenocopies the in-
hibitory activity of AG1478, not supporting EGFR endocytosis. 
A functional EBR is nevertheless required for RALT-mediated 
endocytosis because it provides the docking function necessary 
to relocate cytosolic RALT in proximity of the endocytic ma-
chinery. We posit that RALT mediates EGFR endocytosis thanks 
to its ability of acting as a scaffold for components of the endo-
cytic machinery.JCB • VOLUME 189 • NUMBER 3 • 2010   568
were from Schleicher and Schuell. EGF was from Millipore, tetramethylrho-
damine-EGF  and  tetramethylrhodamine-transferrin  conjugates  were  from 
MDS Analytical Technologies. Rabbit polyclonal anti-EGFR and anti–c-Myc 
antibodies, goat polyclonal antibody to EEA1, and mAb P4D1 anti-Ub and 
anti-GRB2 were purchased from Santa Cruz Biotechnology, Inc. Anti-pEGFR 
antibodies, anti-pERK, anti-pAKT, anti-ERK, and anti-AKT were from Cell 
Signaling Technology. The anti-PIX antibody was from Millipore. Anti-CHC 
(human) (X22) was from EMD, rat antibody to mouse LAMP-1 was from 
eBioscence, and mAbs to adaptin 2 and 2 were from BD. FITC- and 
TRITC-conjugated  goat  anti–rabbit  and  anti–mouse  antibodies,  donkey 
anti–goat, anti–mouse, anti–rabbit, and anti–rat were from Jackson Immuno-
Research Laboratories, Inc. HRP-conjugated goat anti–mouse and anti–
rabbit antibodies were from Bio-Rad Laboratories. mAb 108 (anti-EGFR), 
12CA5 (anti HA), and 9E10 (anti-MYC) were purified in house from hybrid-
oma supernatants. Antibodies to ITSN1 and ITSN2 were raised in rabbits 
against recombinant proteins spanning positions 583–888 of hITSN1 and 
618–885 of hITSN2 and purified by affinity chromatography. Anti-RALT 
affinity-purified HOR3 antibody (rabbit) was described previously (Anastasi   
et al., 2007). The mAb 22D/8 was generated against human RALT and 
recognizes an epitope located in the 325–375 HsRALT sequence.
Cell culture and transfection procedures
NR6 fibroblasts, which lack endogenous EGFR (Pruss et al., 1978), were 
obtained from American Type Culture Collection and grown in DME con-
taining 10% (vol/vol) newborn calf serum. For serum starvation, cells were 
incubated in DME/Ham’s F12 (1:1 mixture) containing 0.2% serum. HEK 293 
cells and the Phoenix ecotropic packaging cell line cells were grown in 
DME containing 10% fetal calf serum. Plasmid DNAs and siRNAs were 
transfected with Lipofectamine 2000 (Invitrogen) according to the manu-
facturer’s protocols. For biochemical studies, transfected HEK 293 cells 
were harvested 48–72 h after transfection. Phoenix cell culture superna-
tants  containing  recombinant  retrovirus  were  harvested  48–72  h  after 
transfection, filtered through a 45-µm disposable filter, added to 8 µg/ml 
polybrene, and incubated with target cells for 3–6 h.
Immunochemical procedures
For most of the experiments reported here, cells were lysed on ice in HNTG 
(50 mM Hepes, pH 7.5, 150 mM NaCl, 10% glycerol, 5 mM EGTA, and 
1% Triton X-100) containing 0.1 mM sodium orthovanadate and protease 
inhibitors. Lysates were cleared of nuclei and debris by centrifugation. Pro-
tein concentration was measured with the BCA kit (Thermo Fisher Scien-
tific).  For  IP/WB  experiments  aimed  at  detecting  ubiquitin-conjugated 
proteins, cells were lysed either in RIPA buffer (50 mM Tris-HCl, pH 7.5, 
150 mM NaCl, 1% Triton X-100, 0.1% SDS, and 0.5% sodium deoxycho-
late) or in boiling 1% SDS. In the latter case, chromosomal DNA was 
sheared by sonication and cleared lysates were diluted with nine volumes 
of HNTG before being subjected to immunoprecipitation.
For immunoprecipitation experiments, antibodies were coupled to   
either protein A or protein G (2–10 µg Ab/IP) and incubated with lysates at 
4°C on a rocker. Immune complexes were washed with lysis buffer and 
eluted with boiling Laemmli buffer. GST pull-down assays were performed as 
described previously (Anastasi et al., 2007). In brief, recombinant proteins 
were solubilized by sonication of bacteria, resuspended in NETN buffer 
(20 mM Tris-HCl, pH 8.0, 100 mM NaCl, 1 mM EDTA, and 0.5% NP-40).   
Lysates were cleared by centrifugation and GST fusion proteins purified onto 
agarose-glutathione sepharose 4B beads. Cell lysates were added to beads 
and binding reactions were allowed to proceed at 4°C under continuous ro-
tation. Beads were washed with HNTG, bound proteins were eluted by boil-
ing in Laemmli buffer and processed for immunoblot analysis.
[
125I]-EGF binding studies
[
125I]-EGF and [
125I]-Tf were either purchased from PerkinElmer or gener-
ated using the IODO-GEN kit according to the supplier’s protocols (Thermo 
Fisher Scientific). Specific activity of EGF was at least 1.5 × 10
5 cpm/ng. 
For binding studies, NR6 derivatives were plated at 4 × 10
4 cells/well in 
24-well gelatin-coated plates. For each time point we used triplicate wells, 
with a fourth well being used to determine background binding in the pres-
ence of a molar excess of unlabeled EGF.
For measuring initial rates of [
125I]-EGF uptake cells, we used the 
protocol described by Sorkin et al. (1992). Cells were incubated with bind-
ing medium (BM; i.e., DME containing 0.2% BSA and 20 mM Hepes,   
pH 7.5) for 10 min in a water bath at 37°C. Binding was initiated by adding 
0.3 ml/well of 1 ng/ml [
125I]-EGF in BM. At the end of binding time, plates 
were put on ice, washed three times with ice-cold PBS, and incubated   
for 5 min with 0.5 ml/well ice-cold elution buffer (0.5 M NaCl/0.2 M 
another important mechanistic difference between the endo-
cytic traffic of kinase-active EGFR and that of EGFR–RALT 
complexes. Cargo sorting into late endosomes in the absence 
of cargo ubiquitylation has been described and may be distin-
guished  from  ubiquitin-dependent  sorting  on  the  basis  of   
differential requirements for components of the ESCRT ma-
chinery (Hislop et al., 2004). We observed that RALT-driven 
degradation of EGFR was consistently slower than that of 
kinase-active  EGFR  (Fig.  1  D),  even  though  the  rates  of 
EGFR down-regulation were similar in control and RALT-
expressing cells. We suppose that this may be due to delayed 
sorting of RALT-bound EGFR molecules into the degradative 
compartment (in the absence of significant recycling to the 
cell surface; see Fig. S2 C), which in turn could reflect mech-
anistic differences between Ub-dependent and Ub-independent 
sorting of EGFR into MVBs. It must be noted that such a delay 
is not detrimental to RALT-dependent suppression of EGFR 
signaling, given that intracellular retention of EGFR by RALT 
is associated to catalytic repression of the receptor. Further 
studies are required to unveil the mechanistic details of RALT-
dependent trafficking of EGFR to late endosomes.
Concluding remarks
The two-tiered mechanism of EGFR suppression enforced by 
RALT has important implications to cell regulation and tumor 
suppression. RALT is expressed in mid to late G1, i.e., when sus-
tained mitogenic signals are necessary to activate the cell cycle 
machinery and direct the abundant RNA and protein synthesis re-
quired for cell size increase. Within this timeframe RALT con-
curs in determining whether EGFR mitogenic signals reach the 
threshold sufficient for G1 completion (Anastasi et al., 2005;   
Reschke et al., 2009). The present study indicates that EGFR 
kinase inactivation by RALT is associated to RALT-mediated 
receptor down-modulation. The two inhibitory mechanisms act 
sequentially: kinase blockade is synchronous with ligand binding, 
whereas EGFR down-regulation reduces receptor expression and 
therefore attenuates responsiveness to subsequent EGF stimula-
tion. We propose that this temporally dilated attenuation of EGFR 
activation is key to determining that only cells receiving a robust 
enough EGF signal are eventually licensed to enter S phase.
RALT endocytic activity is also predicted to protect cells 
from  oncogenic  EGFR  signaling.  Oncogenic  activation  of 
EGFR is associated to, and also dependent on, reduced rates 
of receptor down-regulation. This may be caused by a variety of 
mechanisms, all of which seem to converge on quelling CBL-
dependent EGFR ubiquitylation (Mosesson et al., 2008). Our 
data suggest that RALT may exert a potent tumor suppressor 
function not only through EGFR kinase suppression, but also by 
restoring down-regulation of oncogenic EGFR molecules that 
escape ubiquitylation and thus phenocopy the Y1045F mutant.
Materials and methods
Media, chemicals, and antibodies
Tissue culture media and sera were from Invitrogen and BioWhittaker. All 
chemicals were obtained from Sigma-Aldrich, unless specified otherwise. 
ECL, sepharose-coupled protein A and protein G, and agarose-coupled glu-
tathione were from GE Healthcare. Nitrocellulose and PVDF membranes 569 RALT/MIG6 drives kinase-inactive EGFR endocytosis • Frosi et al.
Mutant (Dc214 and Y1045F) and wtEGFR cDNA clones were subcloned in 
pBabe-puro to obtain vectors suitable for the generation of recombinant 
retrovirus stocks. Fragments encoding the 5SH3 region of human ITSN1 and   
ITSN2 (Pucharcos et al., 2001) were amplified by PCR and subcloned into 
pGEX-6P. Site-directed mutagenesis was performed using the QuikChange 
kit  (Agilent  Technologies).  RNA  was  extracted  from  cultured  cells  using 
Trizol (Invitrogen). Quantitative RT-PCR was performed with the Advantage 
kit (Takara Bio Inc.). Primers for mouse ITSN2 were designed to amplify both 
short and long isoforms (primer sequences are available upon request).
Immunofluorescence analysis
For endocytosis studies, quiescent cells were incubated for 30 min at 4°C 
with EGF (20 ng/ml), washed with cold DME, and then shifted to 37°C for 
the indicated lengths of time in EGF-free DME. Cultures were routinely 
rinsed with PBS (+ Ca
2+/Mg
2+), fixed with 4% paraformaldehyde in PBS 
for 10 min, permeabilized with 0.25% Triton X-100 in PBS at 20°C, and 
processed with antibodies as described previously (Fiorentino et al., 2000; 
Ballarò et al., 2005). For LAMP1 labeling, cells were fixed with methanol 
at 20°C for 5 min. Cells were incubated with primary antibodies and 
subsequently with conjugated secondary antibodies in 1% RIA-grade BSA; 
finally,  coverslips  were  mounted  with  Gelvatol.  A  similar  protocol  was   
adopted for endocytosis of TRITC-conjugated EGF (0.5 µg/ml EGF-TRITC) 
and transferrin (25 µg/ml transferrin-TRITC); cultures were then fixed with 
4% paraformaldehyde and mounted for visualization. For CHC detection, 
cells were rinsed with ice-cold PBS (+ Ca
2+/Mg
2+) and fixed with ice-cold 
4% paraformaldehyde. The samples were routinely examined with a micro-
scope  (model  AX70;  Olympus)  equipped  with  a  40x/0.75  PH2   
and 60x/1.40 oil objective lenses. Images were recorded on a CCD cam-
era  (SPOT;  Diagnostic  Instruments,  Inc.)  run  by  DeltaSystem  software.   
Confocal microscopy was performed with a confocal microscope (TCS-SP; 
Leica) equipped with PLA 40x/1.25 and 60x/1.40 oil objectives. Colocal-
izations were recorded using sequential recording with line average.   
Recorded  images  were  processed  using  Adobe  Photoshop  software   
(using linear curve correction for adjusting brightness and contrast to   
whole images; levels were adjusted equally for all images in a set) and   
ImageJ software.
Online supplemental material
Fig. S1 shows that RALT drives endocytosis and degradation of kinase- 
suppressed EGFR. Fig. S2 shows down-regulation/degradation of EGFR 
Dc214 by RALT as well as the endocytosis-inducing activity of the evolution-
arily conserved 144–411 fragment of RALT. Fig. S3 shows that RALT res-
cues the degradation deficit of EGFR Y1045F independently of receptor 
ubiquitylation. Fig. S4 shows the analysis of SH3-containing proteins in 
RALT-mediated endocytosis. Fig. S5 analyzes the molecular bases of the 
RALT–ITSN physical interaction. Online supplemental material is available 
at http://www.jcb.org/cgi/content/full/jcb.201002032/DC1.
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CH3COOH, pH 2.8). After an additional 1-min wash with elution buffer, 
cell monolayers were dried and lysed with 1N NaOH. Cell surface–associated 
cpm (eluted with elution buffer) and internal cpm (solubilized in NaOH) 
were determined separately from triplicate wells for each time point. Back-
ground binding was determined in parallel in a fourth well containing a 
300-fold molar excess of unlabeled EGF. The internalization rate constant 
(Ke) corresponds to the linear regression coefficient of the internal/surface 
ratio of [
125I]-EGF binding plotted as a function of time (Sorkin et al., 1992), 
and was calculated using Prism4 software (GraphPad Software, Inc.).
Ligand  uptake  assays  at  single  time  points  were  performed  as 
above, except that 3 ng/ml [
125I]-EGF was used when assaying ER chime-
ras. Variables were analyzed by Student’s t test and a probability value of 
P ≤ 0.05 was deemed statistically significant.
For EGFR down-regulation assays (Sigismund et al., 2008), cells 
were plated as above, serum-starved for 16 h, and then incubated with 
100 ng/ml EGF at 37°C. Plates were then put on ice and rinsed with ice-
cold PBS. After eluting cell surface–bound EGF with 0.5 M NaCl/0.2 M 
CH3COONa, cells were rinsed twice with ice cold BM and incubated for 
2 h on ice with BM containing a mixture of 30 ng/ml [
125I]-EGF + 70 ng/ml 
unlabeled EGF. Cells were washed three times with ice-cold PBS and lysed 
with 10 mM NaOH/1% SDS. Specific radioactivity was measured in tripli-
cate wells for each time point after subtraction of background binding (de-
termined  in  parallel  in  a  fourth  well  incubated  with  a  500-fold  molar   
excess of unlabeled EGF). Data obtained from EGF-stimulated were ex-
pressed as percentage of [
125I]-EGF binding, considering 100% the value 
measured in unstimulated cells (i.e., time 0). As an alternative, EGFR down-
regulation was assessed after allowing binding of EGF to cells on ice. Cells 
were then washed with ice-cold DME and shifted at 37°C in EGF-free DME 
for various lengths of time. Residual [
125I]-EGF binding was assessed as de-
scribed above.
For [
125I]-EGF degradation assays (Sigismund et al., 2008), cells 
were plated as above, serum starved for 16 h, and incubated for 45 min 
on ice with BM containing 15 ng/ml [
125I]-EGF. Cells were washed three 
times with ice-cold BM and then incubated at 37°C with 0.5 ml/well BM. 
At the end of the incubation time, plates were put on ice, the medium was 
harvested, and cells washed twice with ice-cold PBS. After eluting cell   
surface–associated [
125I]-EGF with a pH 2.8 wash (see above), cells were 
rinsed with PBS and lysed with 1 mM NaOH. TCA-soluble and TCA-insoluble 
radioactivity was determined in medium and cell lysates. The TCA-soluble 
radioactivity recovered at each time point in medium and cell lysates mea-
sured the fraction of degraded [
125I]-EGF and was expressed as percentage 
of total radioactivity bound to cells (medium + cell surface + internal).
RNA interference
NR6 derivatives were plated at 10
5 cells/35-mm dish and grown for 24 h. 
siRNAs were transfected for 6 h at a concentration of 50 nM using Lipo-
fectamine. For CHC, ITSN1 and ITSN2 knock-down cells were transfected 
twice and analyzed 96 h after the first transfection cycle. Cells were trans-
ferred into 24 well plates for [
125I]-EGF binding studies 24 h after complet-
ing transfection procedures. A fraction of transfected cells was plated 
onto 35-mm dishes to monitor RNAi efficiency by WB or RT-PCR. Smart 
pool siRNAs directed against mouse GRB2, PIX, and RALT were ob-
tained from Thermo Fisher Scientific. Stealth siRNA directed against ITSN1 
(5-CAGCUGGCUUCAAUAUGGAAUCUUU-3), ITSN2 (5-GCAUGU-
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